Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.55 |
| ▸ | CES1 | P23141 | 8/20 | 0.55 |
| ▸ | CES2 | O00748 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990765 | 1.00 | FAAH (0.55) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1685080 | 0.89 | FAAH (0.63) | FAAHCES1MEN1KMT2AHSD17B10 | |
| SCHEMBL3787603 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL3415485 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL3777756 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9435633 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL3777162 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL3778978 | 0.83 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8815415 | 0.82 | FAAH (0.53) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL28986780 | 0.79 | FAAH (0.55) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024103-B1 | METHOD FOR DEPOSITING A NANOMETRIC THIN FILM ON A SUBSTRATE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2014-10-29 | — | — | EP | claimed |
| EP-0930844-B8 | IMPROVED METHODS FOR DIAGNOSTIC IMAGING BY REGULATING THE ADMINISTRATION RATE OF A CONTRAST AGENT | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-0930844-A4 | IMPROVED METHODS FOR DIAGNOSTIC IMAGING BY REGULATING THE ADMINISTRATION RATE OF A CONTRAST AGENT | IMARX PHARMACEUTICAL CORP (US) | 2002-03-13 | — | — | EP | claimed |
| EP-0930844-A1 | IMPROVED METHODS FOR DIAGNOSTIC IMAGING BY REGULATING THE ADMINISTRATION RATE OF A CONTRAST AGENT | IMARX PHARMACEUTICAL CORP. (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1997048337-A1 | IMPROVED METHODS FOR DIAGNOSTIC IMAGING BY REGULATING THE ADMINISTRATION RATE OF A CONTRAST AGENT | IMARX PHARMACEUTICAL CORP. (US) | 1997-12-24 | — | — | WO | claimed |
| US-20230404921-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-12-21 | — | — | US | disclosed |
| WO-2023201399-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-10-26 | — | — | WO | disclosed |
| EP-4236916-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | Royal Melbourne Institute of Technology (AU) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022087686-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-05-05 | — | — | WO | disclosed |
| US-20080241061-A1 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | KEREOS, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241061-A1 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | PHOSPHO1, SGMS1, SGMS2 | FAAH 749/4885CES1 1981/4885CES2 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.